Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — September 2018

Planlagt Fastgjort Låst Flyttet Genmab
2.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • G Offline
    G Offline
    gentogen
    wrote on sidst redigeret af
    #733

    The manageable safety profile and preliminary evidence of clinical activity support active accrual of patients with previously treated EGFR-mutant NSCLC. The first recommended dose of 1050mg is being evaluated in Part 2.

    1 Reply Last reply
    0
    • G Offline
      G Offline
      gentogen
      wrote on sidst redigeret af
      #734

      OBS: fra de første 25 patienter

      1 Reply Last reply
      0
      • D Offline
        D Offline
        Doc4
        wrote on sidst redigeret af
        #735

        @gentogen 9:06 - squamous cell carcinoma (SCC) er cancer i de øverste hudc
        eller og er derfor ofte flade i struktur, så en 20% reduktion i diameter kan oversættes til =<35% reduktion i en 3 dimensionel tumor. Nye tilfælde (UV stråling/sol) i USA er 115 tilfælde/time!!

        1 Reply Last reply
        0
        • R Offline
          R Offline
          Raffles
          wrote on sidst redigeret af
          #736

          Vedr. DuoBody-samarbejdet med Janssen vil Genmab modtage milestones samt royalties. Størrelsen af royalties fremgår ikke af børsmeddelelserne. Er der nogen der har en fornemmelse for %-satserne??

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #737

            For de første 10 programmer er milestone pakken 175 millioner dollars pr program og royalty satsen er formentlig 5-8% eller så.

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #738

              For JNJ-61186372 er royalty satsen dog lige en tand højere - mener Genmab har nævnt 10% eller low teens. Det skyldes at Genmab selv har lavet dette bispecifikke antistof

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #739

                De 10 næste er mlilestone pakken 191 millioner dollars pr program og royalty i samme stil

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  gentogen
                  wrote on sidst redigeret af
                  #740

                  Det Jan omtalte fra Journal of clinical oncology: "Conclusion:
                  Baseline corticosteroid use of ≥ 10 mg of prednisone equivalent was associated with poorer outcome in patients with non–small-cell lung cancer who were treated with PD-(L)1 blockade. Prudent use of corticosteroids at the time of initiating PD-(L)1 blockade is recommended."

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    gentogen
                    wrote on sidst redigeret af
                    #741

                    corticosteroids were associated with decreased overall response rate, progression-free survival, and overall survival with PD-(L)1 blockade.

                    1 Reply Last reply
                    0
                    • G Offline
                      G Offline
                      gentogen
                      wrote on sidst redigeret af
                      #742

                      Just a moment...

                      favicon

                      (ascopubs.org)

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #743

                        Winkel var inde på at isatuximab-folkene måske havde knækket koden i solide. I hvert fald fastholder de kombi-forsøget med Cemiplimab (PD-1 blokker) i prostata cancer og nsclc https://www.clinicaltrials.gov/ct2/show/NCT03367819?term=isatuximab+nsclc&rank=1

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #744

                          Cemiplimab https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-share-first-positive-clinical-data/

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #745

                            Her er det nye studie, som Winkel omtaler, med isa i diverse solide https://www.clinicaltrials.gov/ct2/show/NCT03637764?term=isatuximab&draw=2&rank=11

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #746

                              I hvert fald ser han en fremtid for dara med den subkutane formulering i solide.

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                GeorgeBest
                                wrote on sidst redigeret af
                                #747

                                @Bulder/Sukkeralf/Solsen - I går udtalte Jan at DR5 var 100 gange mere potent end en nøgen antibody. Er dara eller ofa en nøgen antibody? Vil det sige at der er mulighed for at DR5 kan udvikle sig til et meget kraftigere medicament
                                end f.eks. dara?

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  pcf
                                  wrote on sidst redigeret af
                                  #748

                                  http://files.shareholder.com/downloads/JNJ/6383638256x0x983792/7CF8F179-2C61-4A19-A94A-4A630E435993/Pharm_Analyst_Webcast_Slides_FINAL_9-12-18.

                                  1 Reply Last reply
                                  0
                                  • T Offline
                                    T Offline
                                    transalp
                                    wrote on sidst redigeret af
                                    #749

                                    Tak pcf..

                                    1 Reply Last reply
                                    0
                                    • SolsenS Offline
                                      SolsenS Offline
                                      Solsen
                                      wrote on sidst redigeret af
                                      #750

                                      Dara og Ofa er nøgne antistoffer. Ved at stofferne er mere potente opnås bedre sandsynlighed for bedre effekt før toxitet begrænser brugen - lidt generaliseret.

                                      1 Reply Last reply
                                      0
                                      • SolsenS Offline
                                        SolsenS Offline
                                        Solsen
                                        wrote on sidst redigeret af
                                        #751

                                        Vel også bedre sandsynlighed for sc brug.

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #752

                                          DR5 bliver ikke konkurrent til hverken dara eller ofa.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger